title: Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level.
abstract: BACKGROUND
  Cancer patients with chemotherapy-induced anaemia (CIA) often experience cancer-related fatigue (CRF). Darbepoetin alfa (DA) once every 3 weeks (q3w) is an effective and well tolerated erythropoiesis-stimulating agent. This study evaluated DA effectiveness and psychometric properties of the Functional Assessment of Cancer Therapy Fatigue-Subscale (FACT-F) and the Fatigue Symptom Inventory (FSI) in CIA patients.
  
  
  METHODS
  This was a single-centre, prospective study in 100 patients with solid tumour and moderate to severe CRF (visual analogue scale [VAS-F] ≥ 30 mm) who received DA 500 μg q3w during chemotherapy (CT). Clinical data, VAS-F, FACT-F and FSI scores were collected at the beginning and at the end of CT (EOCT).
  
  
  RESULTS
  Mean age was 62.7 years (SD: 12.1), 53.0% were women, 92.0% had ECOG 0-1 and 64% had stage IV tumours. Mean haemoglobin (Hb) significantly increased from baseline 10.2 g/dl to 11.3 g/dl at EOCT. Sixty-five percent of patients showed haematopoietic response at any study point (Hb ≥ 12 g/dl or an increase of ≥ 2 g/dl from baseline), 77% achieved Hb ≥ 11 g/dl and 7% required blood transfusions from week 5 to EOCT. CRF improvement was demonstrated by significant changes in VAS-F, FACT-F and FSI scores (decreases of 21.54, 3.56 and 12.97 points, respectively). FACT-F and FSI questionnaires showed high internal consistency (Cronbach's alpha of 0.98 and 0.98 for FACT-F and FSI, respectively, at the end of study) and satisfactory intra-class coefficients (FACT-F, r=0.73; FSI, r=0.83). There were significant correlations between scores and Hb changes (FACT-F, r=-0.44; FSI, r=-0.54).
  
  
  CONCLUSIONS
  DA 500 μg q3w showed effectiveness in improving Hb and inducing a clinically significant decrease in CRF of patients with solid tumours undergoing CT. The three instruments, VAS-F, FACT-F and FSI, could be suitable for assessing CRF.
authors: Unidad de Oncología Médica, Hospital General de Elda, Elda, Alicante, Spain. gasparesquerdo@yahoo.es
authors: Gaspar
authors: G
authors: Esquerdo
authors: Cristina
authors: C
authors: Llorca
authors: José Manuel
authors: JM
authors: Cervera
authors: David
authors: D
authors: Orts
authors: Asunción
authors: A
authors: Juárez
authors: Alfredo
authors: A
authors: Carrato
references: J Clin Oncol. 1997 Mar;15(3):1218-34
references: 9060566
references: Semin Hematol. 1997 Jul;34(3 Suppl 2):4-12
references: 9253778
references: Cancer. 2002 Jan 15;94(2):528-38
references: 11900238
references: Blood. 2002 Oct 1;100(7):2303-20
references: 12239138
references: Cancer. 2003 Mar 1;97(5):1312-20
references: 12599240
references: J Natl Cancer Inst. 2006 Feb 15;98(4):273-84
references: 16478746
references: J Palliat Care. 1995 Spring;11(1):27-32
references: 7751982
references: Eur J Cancer. 2005 May;41(8):1140-9
references: 15911237
references: Oncologist. 1999;4(1):1-10
references: 10337366
references: J Pain Symptom Manage. 1997 Feb;13(2):63-74
references: 9095563
references: Cancer. 2005 Jan 15;103(2):377-82
references: 15558809
references: Qual Life Res. 1998 May;7(4):301-10
references: 9610214
references: Am J Clin Oncol. 1982 Dec;5(6):649-55
references: 7165009
references: Cancer. 1999 Mar 1;85(5):1186-96
references: 10091805
references: Oncol Nurs Forum. 2004 Sep 17;31(5):977-83
references: 15378098
references: Qual Life Res. 2000;9(7):847-54
references: 11297027
references: Br J Cancer. 2001 Apr;84 Suppl 1:31-7
references: 11308272
references: Eur J Cancer. 2004 Oct;40(15):2201-16
references: 15454245
references: J Clin Oncol. 2001 Jun 1;19(11):2865-74
references: 11387359
references: Oncologist. 2005 Aug;10(7):539-54
references: 16079321
references: Curr Med Res Opin. 2008 Oct;24(10):2931-42
references: 18775103
references: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006704
references: 18254112
references: Ann Oncol. 2004 Jun;15(6):979-86
references: 15151958
references: J Support Oncol. 2003 Jul-Aug;1(2):131-8
references: 15352656
references: Curr Opin Hematol. 2002 May;9(3):228-33
references: 11953669
references: Eur J Cancer. 2007 Jan;43(2):258-70
references: 17182241
references: Oncol Nurs Forum. 1997 Jul;24(6):991-1000
references: 9243585
references: J Pain Symptom Manage. 2002 Dec;24(6):547-61
references: 12551804
references: Ann Oncol. 2003 Apr;14(4):511-9
references: 12649095
references: Semin Hematol. 1997 Jul;34(3 Suppl 2):13-9
references: 9253779
references: Ther Clin Risk Manag. 2007 Jun;3(2):269-75
references: 18360635
references: Cancer. 2002 Aug 15;95(4):888-95
references: 12209734
references: J Clin Oncol. 1998 Oct;16(10):3412-25
references: 9779721
references: Br J Cancer. 2002 Jul 29;87(3):268-76
references: 12177793
references: Br J Haematol. 2003 Aug;122(3):394-403
references: 12877666
references: J Natl Cancer Inst. 2002 Aug 21;94(16):1211-20
references: 12189224
references: J Clin Oncol. 2001 Jun 1;19(11):2875-82
references: 11387360